Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Avantor (AVTR) has been under pressure recently, with the stock showing negative returns over the past week, month, past 3 months and year, alongside a year-to-date decline.
Despite this weaker share performance, the company reports annual revenue of US$6.55b and net income of a US$530.2m loss, with revenue and net income growth both positive on an annual basis.
See our latest analysis for Avantor.
With the share price at US$8.17, Avantor’s 30 day share price return of 27.44% and 1 year total shareholder return decline of 53.31% suggest momentum has been fading as investors reassess growth prospects and risk.
If this pullback has you reassessing your watchlist, it could be a good moment to look across the sector and see what stands out in 32 healthcare AI stocks as a fresh set of ideas.
With Avantor trading at US$8.17, sitting at a discount to analyst targets and an indicated intrinsic value gap, is the market being too harsh on a loss making lab supplier, or already reflecting any future recovery?
Avantor’s most followed valuation story points to a fair value of $10.89 against the recent $8.17 share price, framing the current discount through a detailed set of earnings and cash flow assumptions.
Avantor’s multi-year cost transformation initiative, targeting $400 million in run-rate savings by 2027, coupled with operational efficiency measures and digital infrastructure upgrades, is likely to drive significant margin expansion and enhance free cash flow in coming years, offsetting current competitive pricing pressures.
Curious what sits behind that cost savings target and margin rebuild story? The narrative leans on a specific revenue glidepath and future profit multiple to reach $10.89. The full breakdown shows how those moving parts come together, and how sensitive the result is to even small tweaks in those assumptions.
Result: Fair Value of $10.89 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are still clear risks, including weaker bioprocessing demand and margin pressure from aggressive pricing, that could easily knock this fair value story off course.
Find out about the key risks to this Avantor narrative.
If this mix of risks and potential rewards leaves you undecided, consider reviewing the full balance of 3 key rewards and 1 important warning sign now.